| Drug General Information |
| Drug ID |
D09LZT
|
| Drug Name |
Levomepromazine
|
| Synonyms |
Levoprome
|
| Drug Type |
Small molecular drug
|
| Indication |
Psychosis [ICD10:F20-F29]
|
Approved |
[1]
|
|---|
| Company |
Immunex Corp
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H24N2OS
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
|---|
